Skip to main content
Shandong Sito Bio-technology Co., Ltd. logo

Shandong Sito Bio-technology Co., Ltd. — Investor Relations & Filings

Ticker · 300583 ISIN · CNE100002F36 LEI · 836800ENMRCW06CD2U25 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,388 across all filing types
Latest filing 2025-08-25 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300583

About Shandong Sito Bio-technology Co., Ltd.

https://www.sitobiotech.com

Shandong Sito Bio-technology Co., Ltd. specializes in the research, development, and production of steroid hormone intermediates and active pharmaceutical ingredients (APIs). The company utilizes biological fermentation technology to transform phytosterols into critical precursors, including 4-AD, ADD, and 9-OH-AD. These materials are fundamental components for the synthesis of glucocorticoids, sex hormones, and progestogens. By integrating microbial strain engineering with large-scale industrial fermentation, the company provides high-purity raw materials for global drug manufacturing. Its operations emphasize green chemistry and sustainable production methods, maintaining a comprehensive supply chain that spans from raw material processing to the delivery of specialized chemical intermediates.

Recent filings

Filing Released Lang Actions
股东会议事规则（2025年8月）
Governance Information Classification · 100% confidence The document is titled as "股东会议事规则" which translates to "Shareholders Meeting Rules" or "Rules of Procedure for Shareholders' Meetings". It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including the convening, proposal submission, voting procedures, and other governance-related matters. It references legal frameworks such as the Company Law and Securities Law of China, and includes detailed rules on meeting notices, voting, and resolutions. This document is not a report of financial results, audit, or management discussion, nor is it an announcement or transcript. It is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, it fits best under the category of Governance Information (CGR). The document length and content confirm it is a full governance report, not a brief announcement or notice.
2025-08-25 Chinese
董事会秘书工作细则（2025年8月）
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作细则' which translates to 'Board Secretary Work Rules' and details the duties, qualifications, appointment, and responsibilities of the company's board secretary. It references company governance, legal compliance, and internal control mechanisms. There is no financial data, earnings information, or report publication mentioned. The content focuses on governance practices and internal company rules related to the board secretary role. Therefore, this document fits best under Governance Information (CGR). The document length is 3562 characters, which is sufficient for a detailed governance document and not a brief announcement or certification.
2025-08-25 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "山东赛托生物科技股份有限公司2025 年半年度报告全文" which translates to "Shandong Sito Biotechnology Co., Ltd. 2025 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational performance for the period January 1, 2025 to June 30, 2025. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes financial statements, management commentary, business analysis, and other substantive financial and operational information typical of an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification document. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the board of directors meeting of Shandong Saituo Biotechnology Co., Ltd. It includes approvals of the 2025 semi-annual report and related summaries, profit distribution proposals, amendments to the company charter, and various governance-related rules. The document also mentions that the full reports and detailed contents are published separately on the official disclosure website. The document is not the report itself but a board meeting resolution announcement discussing these reports and governance matters. It is a formal board/management information disclosure about decisions made by the board, including governance and financial report approvals, but does not contain the full financial report or detailed financial data itself. The document length is 4235 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the best classification is Board/Management Information (MANG).
2025-08-25 Chinese
2025年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2025 Half-Year Report Summary' (半年度报告摘要) for Shandong Sitobiotech Co., Ltd. It contains financial data and key metrics for the half-year period, including revenue, net profit, cash flow, and shareholder information. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive details. The length is 2722 characters, which is relatively short and consistent with a summary rather than a full report. The content includes financial figures and business highlights typical of an Interim / Quarterly Report. There is no indication that this is an announcement of a report publication or a certification document. Therefore, the document is best classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-25 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 山东赛托生物科技股份有限公司 regarding the provision for asset impairment losses. It details the reasons, scope, amounts, and accounting basis for the impairment provisions made as of June 30, 2025, which are included in the 2025 half-year report period. The document includes specific financial figures related to impairment losses on receivables and inventory, explanations of the impairment measurement methods, and the impact on net profit and equity. The text is relatively short (2356 characters) and is structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR). Instead, it is a regulatory announcement about a specific accounting event affecting the interim period results. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-08-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.